Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance?

Medical Hypotheses

Volumn 80, Issue 2, 2013, Pages 137-141

  Hoirisch Clapauch, Silvia ^a   Nardi, Antonio E ^b  

^a Hospital Federal dos Servidores do Estado   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID ANTIBODY; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; FEMALE; HIPPOCAMPUS; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; NERVE CELL PLASTICITY; PROTEIN C DEFICIENCY; PSYCHOSIS; REMISSION; THROMBOPHILIA;

ADOLESCENT; ADULT; BRAZIL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURONAL PLASTICITY; PLASMINOGEN ACTIVATORS; PSYCHOTIC DISORDERS; REMISSION INDUCTION; THROMBOEMBOLISM; WARFARIN;

EID: 84872319204     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.11.011     Document Type: Article

References (36)

1. Van Neste E.G., Verbruggen W., Leysen M. Deep venous thrombosis and pulmonary embolism in psychiatric settings. Eur J Psychiatry 2009, 23:19-30.
2. Parker C., Coupland C., Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010, 341:c4245.
3. Masopust J., Maly R., Andrys C., Valis M., Bazant J., Hosak L. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry 2011, 11:2.
4. Ehrlich S., Brauns S., Yendiki A., et al. Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls. Schizophr Bull 2012, 38:1050-1062.
5. Velakoulis D., Wood S.J., Wong M.T., et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006, 63:139-149.
6. McEwen B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005, 54(5 Suppl. 1):20-23.
7. Lahtinen L., Huusko N., Myöhänen H., et al. Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus. Neuroscience 2009, 163:316-328.
8. Melchor J.P., Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemostasis 2005, 93:655-660.
9. Madani R., Hulo S., Toni N., Madani H., Steimer T., Muller D., et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. Eur Mol Biol Organiz J 1999, 18:3007-3012.
10. Ito M., Nagai T., Kamei H., et al. Involvement of tissue plasminogen activator plasmin system in depolarization-evoked dopamine release in the nucleus accumbens of mice. Mol Pharmacol 2006, 70:1720-1725.
11. Nagai T., Yamada K., Yoshimura M., et al. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci 2004, 101:3650-3655.
12. Lodge D.J., Grace A.A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci 2011, 32:507-513.
13. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview diagnostic (SCID) for DSM-IV axis I disorders: clinician version (SCID-CV) 1997, American Psychiatric Press, Washington.
14. Colucci M., Binetti B.M., Tripodi A., Chantarangkul V., Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004, 103:2157-2161.
15. Colucci M., Cattaneo M., Martinelli I., Semeraro F., Binetti B.M., Semeraro N. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J Thromb Haemostasis 2008, 6:1571-1577.
16. Asplund-Carlson A., Hamsten A., Wiman B., Carlson B. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993, 36:817-825.
17. Guest P.C., Wang L., Harris L.W., et al. Increased levels of circulating insulin related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 2010, 15:118-119.
18. Schachter M., Raziel A., Friedler S., Strassburger D., Bern O., Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003, 8:721-727.
19. Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M.A. Antiphospholipid syndrome. Lancet 2010, 376:1498-1509.
20. Schwartz M., Rochas M., Weller B., et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998, 59:20-23.
21. Kurtz G., Muller N. The antiphospholipid syndrome and psychosis. Am J Psychiatry 1994, 151:1841-1842.
22. Plaisier M., Koowijk P., Willems S., van Hinsbergh V.W.M., Helmerhorst F.M. The expression of pericellular acting proteases in human first trimester decidua. Mol Hum Reprod 2008, 14:41-51.
23. Dusse L.M., Rio R.A., Pinheiro M.B., Cooper A.J., Lwaleed B.A. Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation. Clinica Chimica Acta 2011, 412:17-21.
24. Bergink V., Lambregtse-van den Berg M.P., Koorengevel K.M., Kupka R., Kushner S.A. First-onset psychosis occurring in the postpartum period: a prospective cohort study. J Clin Psychiatry 2011, 72:1531-1537.
25. Joy S. Chief Editor: Chelmow D. Postpartum depression. Available from: -overview Updated: Mar 6, 2012. (retrieved Nov 23, 2012). http://emedicine.medscape.com/article/271662.
26. Binder B.R., Christ G., Gruber F., et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002, 17:56-61.
27. Sakata Y., Loskutoff D.J., Gladson C.L., Hekman C.M., Griffin J.H. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986, 68:1218-1223.
28. Cesarman-Maus G., Hajjar K.A. Molecular mechanisms of fibrinolysis. Br J Haematol 2005, 129:307-321.
29. Eaton W.W., Pedersen M.G., Nielsen P.R., Mortensen P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disorders 2010, 12:638-646.
30. Ainiala H., Loukkola J., Peltola J., Korpela M., Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001, 57:496-500.
31. Kwiecinski J., Klak M., Trysberg E., Blennow K., Tarkowski A., Jin T. Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus. Arth Rheum 2009, 60:2094-2101.
32. Wu Y.P., Siao C.J., Lu W., et al. The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J Cell Biol 2000, 148:1295-1304.
33. Rassi A., Veras A.B., dos Reis M., et al. Prevalence of psychiatric disorders in patients with polycystic ovary syndrome. Compr Psychiatry 2010, 51:599-602.
34. Tsiouris J.A. Metabolic depression in hibernation and major depression: an explanatory theory and an animal model of depression. Med Hypotheses 2005, 65:829-840.
35. Arrigo B.A. The psychological effects of solitary confinement on prisoners in supermax units. Reviewing what we know and recommending what should change. Int J Offender Ther Comp Criminol 2008, 52:622-640.
36. Clapauch S.H., Benchimol-Barbosa P.R. Warfarin resistance and caffeine containing beverages. Int J Cardiol 2012, 156:e4-e5.